Skip to main content
. Author manuscript; available in PMC: 2014 Jun 3.
Published in final edited form as: Hypertens Res. 2011 May 12;34(7):869–875. doi: 10.1038/hr.2011.44

Figure 4.

Figure 4

Effect of hCRP and rosuvastatin on vascular expression of AT1 receptors, NAD(P)H oxidase subunits and SOD-1. (A) Representative immunoblot analysis for AT1 receptor, p22 phox, gp91 phox and SOD-1 expression in vasculature. (B) Densitometric analysis (Control = 1) of immunoblots shows that CRP-induced increases in AT1 receptor, p22 phox and gp91phox expression were abolished by rosuvastatin treatment (p<0.05). SOD-1 was downregulated by AAV-hCRP injection, but normalized by rosuvastatin treatment (p<0.05). (C) Superoxide release is expressed as relative chemiluminescence per milligram of aortic tissue (Control = 100) (p<0.05). Data represent mean ± SEM. * p<0.05 vs. control group. # p<0.05 vs. AAV-hCRP group.